2025
A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3.
Zhang J, Cai J, Wang H, Yu Y, Bosch-Barrera J, Bernabé R, Andric Z, Badin F, Okuma Y, Paik P, Naidoo J, Kalofonos H, Wang B, Jotte R, Pennell N, Riess J, Doroshow D, Nishio M, Alatorre-Alexander J, Lu S. A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3. Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps8664.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalFirst-line treatmentMetastatic non-small cell lung cancerCell lung cancerPD-1PD-L1Metastatic diseaseFirst-line treatment of metastatic non-small cell lung cancerLung cancerPD-L1 tumor proportion scoreTreatment of metastatic non-small cell lung cancerProgrammed cell death protein 1Cell death protein 1Programmed death-ligand 1Randomized phase 3 studyStandard first-line treatmentDevelopment of metastatic diseaseDisease control rateTumor proportion scoreDeath-ligand 1Platinum-doublet chemotherapyTargeting PD-1Duration of responseFirst-line therapyFirst-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
Shen L, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Hu N, McCraith S, Liu T. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. Journal Of Clinical Oncology 2025, 43: 392-392. DOI: 10.1200/jco.2025.43.4_suppl.392.Peer-Reviewed Original ResearchBlinded independent central reviewObjective response rateProgression-free survivalCombined positive scorePD-L1CheckMate 649Overall survivalFollow-upSurvival benefitPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Long-term survival benefitStudy populationDual primary endpointsDeath-ligand 1Gastroesophageal junction cancerDuration of responseAdvanced gastric cancerIndependent central reviewOS ratesJunction cancerCentral reviewPrimary endpointFirst-lineNivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.
Janjigian Y, Moehler M, Ajani J, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary J, Elimova E, Bruges R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, McCraith S, Hu N, Zhang J, Shitara K. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649. Journal Of Clinical Oncology 2025, 43: 398-398. DOI: 10.1200/jco.2025.43.4_suppl.398.Peer-Reviewed Original ResearchProgression-free survivalBlinded independent central reviewObjective response rateCombined positive scorePD-L1Overall survivalFollow-upCheckMate 649OS ratesPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Anti-PD-1Death-ligand 1Duration of responseIndependent central reviewMinimum follow-upFollow-up resultsLong-term survivalOS benefitCentral reviewCombination therapyFirst-linePrimary endpointNivolumab
2024
Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial
Choueiri T, Kuzel T, Tykodi S, Verzoni E, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski R, Folefac E, Castonguay V, Lee C, Vaishampayan U, Miller W, Bhagavatheeswaran P, Wang Y, Gupta S, DeSilva H, Lee C, Escudier B, Motzer R. Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial. ESMO Open 2024, 9: 104073. PMID: 39642635, PMCID: PMC11667034, DOI: 10.1016/j.esmoop.2024.104073.Peer-Reviewed Original ResearchConceptsAdvanced renal cell carcinomaNivolumab + ipilimumabProgression-free survivalDuration of responseMedian duration of responseProgression-free survival ratesProgrammed death-ligand 1Renal cell carcinomaImmuno-oncologyOpen-labelCell carcinomaPatients treated with nivolumabTyrosine kinase inhibitor therapyTreatment-related adverse eventsLymphocyte activation gene-3Death-ligand 1Kinase inhibitor therapyAssessment of combination therapyEffective combination regimenImmuno-oncology studiesCombination regimenInhibitor therapyLAG-3Combination therapySecondary endpointsImmune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups
Leone A, Mai A, Fong K, Yap D, Kato K, Smyth E, Moehler M, Seong J, Sundar R, Zhao J, Pietrantonio F. Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups. ESMO Open 2024, 9: 103962. PMID: 39426081, PMCID: PMC11533044, DOI: 10.1016/j.esmoop.2024.103962.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCombined positive scoreBenefit of immune checkpoint inhibitorsCheckpoint inhibitorsOS benefitOverall survivalAnti-programmed cell death protein 1Kaplan-Meier (KM) plotsEfficacy of immune checkpoint inhibitorsFirst-line immune checkpoint inhibitorsPD-L1 combined positive scoreProgrammed death ligand 1 subgroupsCell death protein 1Programmed death-ligand 1Patient-level meta-analysesPatient-Level Meta-AnalysisDeath-ligand 1Advanced gastroesophageal adenocarcinomaRandomized clinical trialsCheckMate-649KEYNOTE-062Gastroesophageal adenocarcinomaTherapeutic optionsClinical trialsKM plotsImmune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers
Kim J, Hong J, Lee J, Jung M, Choi E, Cho N, Kang G, Kim S. Immune microenvironmental heterogeneity according to tumor DNA methylation phenotypes in microsatellite instability-high colorectal cancers. Cancer Immunology, Immunotherapy 2024, 73: 215. PMID: 39235590, PMCID: PMC11377388, DOI: 10.1007/s00262-024-03805-3.Peer-Reviewed Original ResearchConceptsProgrammed death-ligand 1Tumor-infiltrating lymphocytesMicrosatellite instability-high colorectal cancerCombined positive scoreTumor proportion scoreTumor mutational burdenCD8+ tumor-infiltrating lymphocytesMicrosatellite instability-highTumor-infiltrating immune cellsCpG island methylator phenotypeColorectal cancerCIMP-high tumorsDensity of CD8+ tumor-infiltrating lymphocytesProgrammed death-ligand 1 tumor proportion scoreCIMP-highConsensus molecular subtype 1Cytolytic activity scoreWhole-slide immunohistochemistryDeath-ligand 1Tumor immune microenvironmentMethylator phenotypeMicrosatellite instability-high tumorsTumor DNA methylationDNA methylation phenotypeCpG island methylator phenotype statusNivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.
Elimova E, Shitara K, Moehler M, Ajani J, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary J, Bruges Maya R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Feeney K, Wang R, Nathani R, Janjigian Y. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649. Journal Of Clinical Oncology 2024, 42: 4040-4040. DOI: 10.1200/jco.2024.42.16_suppl.4040.Peer-Reviewed Original ResearchProgression-free survivalBlinded independent central reviewCombined positive scoreObjective response ratePD-L1Overall survivalFollow-upCheckMate 649Clinically meaningful progression-free survivalPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Dual primary endpointsHER2+ patientsDeath-ligand 1Analysis of OSIndependent central reviewLong-term efficacyFollow-up resultsEarly Follow-upClinically Meaningful ImprovementsMedian OSOS benefitPD-1Central reviewFirst-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
Ren S, Wang X, Han B, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial. Journal For ImmunoTherapy Of Cancer 2024, 12: e007227. PMID: 38388167, PMCID: PMC10882294, DOI: 10.1136/jitc-2023-007227.Peer-Reviewed Original ResearchConceptsMetastatic NSCLC patientsDisease control rateProgression-free survivalFirst-line treatmentNSCLC patientsOS ratesPD-L1Overall survivalOpen-labelSafety profileTreatment-related adverse events of grade 3Adverse events of grade 3Combination of immune-checkpoint inhibitorsEvents of grade 3Median progression-free survivalPhase 2 basket trialProgrammed death-ligand 1Treatment-related adverse eventsGrade 5 hemoptysisImmune-checkpoint inhibitorsPD-L1 TPSSafety of camrelizumabSolid Tumors V.1.1Death-ligand 1Response Evaluation CriteriaNivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
Shitara K, Moehler M, Ajani J, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary J, Elimova E, Bruges Maya R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Feeney K, Wang R, Nathani R, Janjigian Y. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649. Journal Of Clinical Oncology 2024, 42: 306-306. DOI: 10.1200/jco.2024.42.3_suppl.306.Peer-Reviewed Original ResearchProgression-free survivalBlinded independent central reviewCombined positive scoreObjective response ratePD-L1Overall survivalFollow-upCheckMate 649Clinically meaningful progression-free survivalPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Dual primary endpointsHER2+ patientsDeath-ligand 1Analysis of OSIndependent central reviewLong-term efficacyFollow-up resultsEarly Follow-upClinically Meaningful ImprovementsMedian OSOS benefitPD-1Central reviewFirst-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up.
Shen L, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Wang R, McCraith S, Liu T. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up. Journal Of Clinical Oncology 2024, 42: 318-318. DOI: 10.1200/jco.2024.42.3_suppl.318.Peer-Reviewed Original ResearchBlinded independent central reviewProgression-free survivalCombined positive scorePD-L1Overall survivalFollow-upCheckMate 649Safety profilePD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Clinically meaningful survival benefitStudy populationDual primary endpointsObjective response rateDeath-ligand 1Gastroesophageal junction cancerYrs of follow-upAdvanced gastric cancerIndependent central reviewOS ratesJunction cancerSurvival benefitCentral reviewFirst-line
2023
High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
Robert M, Rüschoff J, Jasani B, Graham R, Badve S, Rodriguez-Justo M, Kodach L, Srivastava A, Wang H, Tang L, Troncone G, Rojo F, Van Treeck B, Pratt J, Shnitsa I, Kumar G, Karasarides M, Anders R. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma. Modern Pathology 2023, 36: 100154. PMID: 36925069, DOI: 10.1016/j.modpat.2023.100154.Peer-Reviewed Original ResearchConceptsCombined positive scorePD-L1 expressionCheckpoint inhibitor therapyPD-L1Tumor cellsImmune cellsIntraclass correlation coefficientInhibitor therapyInterpretation of PD-L1 expressionPD-L1 combined positive scoreInterobserver variabilityBiopsy samplesEvaluate PD-L1 expressionImmune checkpoint inhibitor therapyInterpathologist agreementProgrammed death-ligand 1PD-L1 immunohistochemistryDeath-ligand 1Variable intensity of stainingIntensity of stainingPositive scoresRetrospective histologic reviewPretreatment biopsiesTumor stainingHistologic review
2022
Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
Yeong J, Lum H, Teo C, Tan B, Chan Y, Tay R, Choo J, Jeyasekharan A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 2022, 25: 741-750. PMID: 35661944, PMCID: PMC9226082, DOI: 10.1007/s10120-022-01301-0.Peer-Reviewed Original ResearchConceptsCombined positive scorePD-L1 combined positive scoreTumor proportion scorePD-L1Gastric cancerImmune cellsPD-L1 immunohistochemistry assaysProgrammed death-ligand 1Resection of gastric cancerStandard-of-care treatmentBackgroundImmune checkpoint inhibitorsGastric cancer immunotherapyPD-L1 positivityPD-L1 scoringPD-L1 immunohistochemistryDeath-ligand 1Metastatic gastric cancerPD-L1-positive samplesInter-assay concordanceCheckpoint inhibitorsDako 22C3ICI therapyCross-sectional studyCancer immunotherapyPatient selectionChoice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.
Tay R, Yeong J, Lum J, Teo C, Tan B, Chan Y, Choo J, Jeyasekhran A, Miow Q, Loo L, Yong W, Sundar R. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Journal Of Clinical Oncology 2022, 40: 4026-4026. DOI: 10.1200/jco.2022.40.16_suppl.4026.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune checkpoint inhibitor therapyPD-L1 CPSTumor proportion scorePD-L1Gastric cancerTissue microarrayImmune cellsPatients treated with ICI therapyPD-L1 expression statusPD-L1 immunohistochemistry assaysProgrammed death-ligand 1Resection of gastric cancerStandard-of-care treatmentGastric cancer immunotherapyPD-L1 scoringPD-L1 immunohistochemistryPD-L1 positivityDeath-ligand 1Metastatic gastric cancerPD-L1-positive samplesInter-assay concordanceNational University HospitalWhole slide analysisCut-offImpact of hyperthermic intraperitoneal chemotherapy on genomic heterogeneity of peritoneal metastases in stage IV gastroesophageal adenocarcinoma.
Sood D, Fefferman M, Reizine N, Morgan R, Ong C, Dhiman A, Turaga K, Catenacci D, Eng O. Impact of hyperthermic intraperitoneal chemotherapy on genomic heterogeneity of peritoneal metastases in stage IV gastroesophageal adenocarcinoma. Journal Of Clinical Oncology 2022, 40: 312-312. DOI: 10.1200/jco.2022.40.4_suppl.312.Peer-Reviewed Original ResearchHyperthermic intraperitoneal chemotherapyTumor mutational burdenLaparoscopic hyperthermic intraperitoneal chemotherapyTumor mutation burden levelPD-L1 statusPD-L1 expressionPD-L1Gastroesophageal adenocarcinomaPeritoneal metastasisOverall survivalSystemic chemotherapyIntraperitoneal chemotherapyImpact of hyperthermic intraperitoneal chemotherapyEffect of hyperthermic intraperitoneal chemotherapyMedian peritoneal cancer indexResponse to systemic chemotherapyProgrammed death-ligand 1Genomic heterogeneityMedian overall survivalPeritoneal cancer indexTemporal genomic heterogeneityDeath-ligand 1Response to therapyDatabase of patientsTumor suppressor genePredictive Biomarkers of Immunotherapy Efficacy in RCC and Their Role in Non-metastatic Stages
Malhotra J, Meza L, Salgia N, Pal S. Predictive Biomarkers of Immunotherapy Efficacy in RCC and Their Role in Non-metastatic Stages. 2022, 221-227. DOI: 10.1007/978-3-030-80546-3_17.ChaptersManagement of metastatic renal cell carcinomaProgrammed death-ligand 1Renal cell carcinomaMedian survivalCell carcinomaMetastatic renal cell carcinomaDeath-ligand 1Non-metastatic stageCheckpoint inhibitorsImmunotherapy efficacySequence therapyPredictive biomarkersInterleukin-2Exploratory markersClinical practiceCarcinomaClinical judgmentSurvivalBiomarkersPrognosisTherapyPatientsEfficacy
2021
Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma
Zhao J, Yap D, Chan Y, Tan B, Teo C, Syn N, Smyth E, Soon Y, Sundar R. Low Programmed Death-Ligand 1–Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2021, 40: 392-402. PMID: 34860570, DOI: 10.1200/jco.21.01862.Peer-Reviewed Original ResearchConceptsProgrammed death-ligand 1Combined positive scoreImmune checkpoint inhibitorsKEYNOTE-062First-line treatmentCheckMate-649Checkpoint inhibitorsEsophageal adenocarcinomaKaplan-MeierEstimate time-to-event outcomesFirst-line immune checkpoint inhibitorsPD-L1 combined positive scoreProgrammed death ligand 1 subgroupsPatients treated with pembrolizumabPD-L1-expressing tumorsRandomized phase III trialEfficacy of ICIsPD-L1 subgroupsProgression-free survivalDeath-ligand 1Phase III trialsUS Food and Drug AdministrationPrimary manuscriptsFood and Drug AdministrationCPS-1
2020
Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma
Yan M, Chang Y, Raghavan V, Dong E, Klein C, Nielsen T, Paulson J, Hatzi K. Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma. Blood 2020, 136: 29-30. DOI: 10.1182/blood-2020-134867.Peer-Reviewed Original ResearchProgrammed death-ligand 1Current equity holderMacrophage infiltrationM1 macrophagesF. Hoffmann-La RocheLymphoma microenvironmentMacrophage scoreMacrophage signatureClinical outcomesProgrammed death-ligand 1 mRNA expressionDiffuse large B-cell lymphomaNatural killer (NK) cellsAssociated with shorter PFSCD20-targeted monoclonal antibodyNK cell-mediated ADCCPrognostic trendTreatment outcomesLarge B-cell lymphomaRecruitment of M1 macrophagesPhase III clinical trialsImmune microenvironment profilesInternational Prognostic IndexResponse to immunochemotherapyDeath-ligand 1Improved overall survivalHeterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
White M, Schulte J, Xue L, Berger Y, Schuitevoerder D, Vining C, Kindler H, Husain A, Turaga K, Eng O. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. British Journal Of Cancer 2020, 124: 564-566. PMID: 33100328, PMCID: PMC7851380, DOI: 10.1038/s41416-020-01130-x.Peer-Reviewed Original ResearchConceptsProgrammed death-ligand 1 expressionProgrammed death-ligand 1Malignant peritoneal mesotheliomaImmune checkpoint inhibitionCheckpoint inhibitionIntraperitoneal chemotherapyPeritoneal mesotheliomaLevel of PD-L1 expressionUpregulation of programmed death ligand 1Malignant peritoneal mesothelioma patientsTreatment-naive cohortPD-L1 expressionDeath-ligand 1Patient tumor biopsiesSomatic mutation burdenCytotoxic therapyTumor biopsiesMutational burdenGermline mutationsTreatment strategiesChemotherapyPatientsMultiple time pointsTime pointsMesothelioma
2019
PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis
Tan W, Tan W, Inman B. PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis. Bladder Cancer 2019, 5: 211-223. PMID: 31867425, PMCID: PMC6919639, DOI: 10.3233/blc-190238.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsProgression-free survivalMetastatic urothelial carcinomaImmune checkpoint inhibitor therapyProgrammed death-ligand 1Response ratePooled Kaplan-Meier analysisBiomarker statusHigher overall response rateAnalyzed response ratesMetastatic urothelial cancerDeath-ligand 1Programmed death-1Platinum-based chemotherapyPD-L1/PD-1Kaplan-Meier analysisMeta-analysisOverall response rateProportional hazards survival analysisSystematic reviewComprehensive literature searchCheckpoint inhibitorsDeath-1PD-1Platinum therapy
2016
Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
Lee L, Cavalcanti M, Segal N, Hechtman J, Weiser M, Smith J, Garcia-Aguilar J, Sadot E, Ntiamoah P, Markowitz A, Shike M, Stadler Z, Vakiani E, Klimstra D, Shia J. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology 2016, 29: 1433-1442. PMID: 27443512, PMCID: PMC5083129, DOI: 10.1038/modpathol.2016.139.Peer-Reviewed Original ResearchConceptsProgrammed death-ligand 1PD-1-positive tumor-infiltrating lymphocytesProgrammed death-ligand 1 expressionTumor-infiltrating lymphocytesProgrammed death-1Mismatch repair-deficient colorectal carcinomasRecurrence-free survivalAnti-PD-1 therapyPD-L1 expressionColorectal carcinomaMismatch repair-deficient tumorsPredictive markerPrognostic impact of tumor-infiltrating lymphocytesResponse to anti-PD-1 therapyHigh programmed death ligand-1Impact of tumor-infiltrating lymphocytesProgrammed death ligand 1 levelPD-1 levelsTumor PD-L1 expressionProgrammed death-1 expressionAssociated with better prognosisMismatch repair-proficient tumorsImmune checkpoint blockadePD-1 expressionPD-L1 immunohistochemistry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply